| Literature DB >> 19727389 |
Yuki Kawakubo1, Hitoshi Kuwabara, Kei-Ichiro Watanabe, Michiko Minowa, Toshikazu Someya, Iwao Minowa, Toshiaki Kono, Hisami Nishida, Toshiro Sugiyama, Nobumasa Kato, Kiyoto Kasai.
Abstract
BACKGROUND: Dysfunctions of the prefrontal cortex have been previously reported in individuals with autism spectrum disorders (ASD). Previous studies reported that first-degree relatives of individuals with ASD show atypical brain activity during tasks associated with social function. However, developmental changes in prefrontal dysfunction in ASD and genetic influences on the phenomena remain unclear. In the present study, we investigated the change in hemoglobin concentration in the prefrontal cortex as measured with near-infrared spectroscopy, in children and adults with ASD during the letter fluency test. Moreover, to clarify the genetic influences on developmental changes in the prefrontal dysfunction in ASD, unaffected siblings of the ASD participants were also assessed. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2009 PMID: 19727389 PMCID: PMC2731203 DOI: 10.1371/journal.pone.0006881
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of Participants.
|
|
| |||
|
|
|
| ||
|
|
|
| ||
|
| 12/2 | 4/8 | 12/2 | p<.01 |
|
| 12.7±3.4 | 11.1±3.0 | 10.6(2.8 | p = .25 |
|
| (6.6(17.3) | (5.9(15.8) | (5.8(16.6) | |
|
| 95.2(8.4 | 103.5(12.9 | 102.1(6.5 | p = .065 |
|
| (85(108) | (85(121) | (90(114) | |
|
| 28.7(5.3 | 15.4(0.8 | ---- | p<.001 |
|
| (22(40) | (15(17.5) | ---- | |
|
|
| |||
|
|
|
| ||
|
|
|
| ||
|
| 9/4 | 7/5 | 9/4 | p = .81 |
|
| 26.7±6.1 | 24.3±4.3 | 25.8±5.1 | p = .53 |
|
| (18.3∼39.0) | (18.9∼35.4) | (21.4∼37.4) | |
|
| 104.7±11.5 | 105.4±8.7 | 111.3±12.6 | p = .27 |
|
| (86∼123) | (92∼117) | (92∼128) | |
|
| 29.6±6.6 | 15.6±0.8 | ---- | p<.001 |
|
| (19∼40.5) | (15∼17.5) | ---- |
CARS, Childhood Autism Rating Scale; f, female; m, male;
IQ was evaluated with the WISC-III, except for 1 ASD child estimated IQ by four subtests of the WAIS-R.
For all ASDs and 4 siblings IQs were evaluated with the WAIS-R, for 8 siblings and all controls IQs were estimated by four subtests of the WAIS-R.
The individual's data in ASD group.
| case | sex | age | handedness | subtype | CARS | medication (mg/day) | EIQ | VIQ | PIQ | FIQ | LFT | |
| Child | 1 | f | 6.6 | R | Au | 35.5 | none | . | 104 | 100 | 102 | 3 |
| 2 | m | 7.6 | R | Au | 31 | none | . | 77 | 99 | 86 | 5 | |
| 3 | m | 8.9 | R | Au | 40 | Risperidone 1, Sodium valproate 200 | . | 101 | 94 | 98 | 5 | |
| 4 | m | 9.3 | R | As | 32.5 | Levomepromazine 10, Lithium 200, Carbamazepine 200 | . | 101 | 113 | 107 | 2 | |
| 5 | m | 10.6 | R | Au | 27 | Risperidone 2 | . | 85 | 107 | 95 | 1 | |
| 6 | f | 13.0 | R | PDD-NOS | 23 | none | . | 120 | 93 | 108 | 6 | |
| 7 | m | 13.5 | R | Au | 31.5 | Pimozide 3, Levomepromazine 5, Clonazepam 1 | . | 86 | 100 | 92 | 3 | |
| 8 | m | 13.5 | R | As | 23 | Sulpiride 300, Estazoram 2 | . | 87 | 85 | 85 | 7 | |
| 9 | m | 14.0 | R | PDD-NOS | 22 | none | . | 104 | 94 | 99 | 6 | |
| 10 | m | 14.1 | R | As | 30.5 | Haloperidol 9, Sodium valproate 600 | . | 87 | 87 | 86 | 2 | |
| 11 | m | 15.2 | L | PDD-NOS | 22.5 | Risperidone 2, Zotepine 75, Lithium 200, Nitrazepam 5 | . | 81 | 99 | 88 | 7 | |
| 12 | m | 16.2 | R | PDD-NOS | 28.5 | Risperidone4, Chlorpromazine 25, Levomepromazine 200, Carbamazepine 800, | . | 84 | 92 | 86 | 4 | |
| Fluboxamine 75, Nitrazepam 5, Pentobarbital 50, Phenobarbital 40 | ||||||||||||
| 13 | m | 17.3 | R | As | 28 | Haloperidol 4, Levomepromazine 150, Carbamazepine 1200 | 106 | . | . | . | 5 | |
| 14 | m | 17.6 | R | As | 27 | Risperidone 2, Carbamazepine600, Sodium valproate400 | . | 96 | 94 | 95 | 8 | |
| Adult | 1 | f | 18.3 | R | PDD-NOS | 25 | none | . | 108 | 91 | 101 | 4 |
| 2 | m | 20.4 | R | As | 33.5 | Carbamazepine 200, Paroxetine 20, Brotizolam 0.5 | . | 101 | 101 | 101 | 4 | |
| 3 | m | 21.9 | R | PDD-NOS | 19 | Methylphenidate | . | 98 | 108 | 102 | 8 | |
| 4 | m | 22.1 | R | As | 26 | Sodium valproate 200, Paroxetine 20, Ethyl loflazepate 1 | . | 103 | 90 | 98 | 8 | |
| 5 | m | 23.8 | R | As | 35 | None | . | 109 | 95 | 104 | 12 | |
| 6 | m | 24.0 | R | Au | 38 | Risperidone 4, Quetiapine450, Chlorpromazine 25, Sodium valproate 600, | . | 78 | 105 | 86 | 8 | |
| Fluvoxamine 100, Bromazepam 4 | ||||||||||||
| 7 | m | 26.0 | R | PDD-NOS | 20.5 | Risperidone, Fluboxamine, Etizolam | . | 97 | 95 | 95 | 8 | |
| 8 | m | 26.0 | R | As | 40.5 | Setiptiline 2, Triazolam 0.25, Ethyl loflazepate 1 | . | 100 | 130 | 113 | 7 | |
| 9 | f | 28.3 | R | As | 35 | Fluvoxamine 75 | . | 74 | 113 | 90 | 5 | |
| 10 | m | 29.5 | R | As | 24.5 | Sodium valproate 600, Fluboxamine 75 | . | 136 | 103 | 123 | 9 | |
| 11 | f | 31.1 | R | As | 30 | None | . | 121 | 103 | 114 | 10 | |
| 12 | f | 36.3 | R | As | 29.5 | Pimozide 1, Clomipramine 20 | . | 124 | 116 | 122 | 10 | |
| 13 | m | 39.0 | R | As | 28 | Sodium valproate 200, Fluvoxamine 100, Zolpidem 5 | . | 113 | 108 | 112 | 9 |
CARS, Childhood Autism Rating Scale; EIQ, estimated IQ; VIQ, verbal IQ; PIQ, performance IQ; FIQ, Full-scale IQ; LFT, the number of words generated during the letter fluency task; L, left; R, right; f, female; m, male; Au, autistic disorder; As, asperger disorder; PDD-NOS, pervasive developmental disorder not otherwise specified.
The dosages for Case 3 and 7 were unavailable.
Mean [Hb] (SD) in each group.
| child group | oxyHb | deoxyHb | ||
| R | L | R | L | |
| ASD | 0.65(0.89) | 0.38(0.88) | −0.08(0.32) | −0.17(0.25) |
| Sibling | 0.41(0.73) | 0.59(0.75) | 0.01(0.55) | −0.05(0.33) |
| Control | 1.17(1.21) | 1.16(1.12) | −0.10(0.34) | −0.22(0.32) |
oxyHb, oxyhemoglobin; deoxyHb, deoxyhemoglobin; L, left; R, right.